Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Quick Read

JNJ and ARCC anchor opposite ends of the yield spectrum, with $4 million at 3% on one side and $1.4 million at 10% on the other, each carrying proportional principal risk. High-yield portfolios start with larger checks, but flat payouts erode purchasing power while dividend-growth income compounds over 10 to 15 years. Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.

Twelve thousand dollars a month in dividend income sounds simple enough until you start doing the math. Many investors assume they can reach that number with a seven-figure portfolio and a handful of high-yield stocks. In reality, the capital required ranges from about $1.4 million to more than $4 million, depending on the yield you target, the risks you are willing to accept, and how much future dividend growth you are willing to sacrifice for income today.Thinkstock

Before sizing the portfolio, size the goal. Twelve thousand dollars a month works out to $144,000 a year, which is roughly what a senior engineer, experienced attorney, or successful small-business owner might earn. But replacing a salary and replacing a lifestyle are not the same thing. Once payroll taxes, retirement contributions, commuting costs, and other work-related expenses disappear, many households need substantially less money than their gross income suggests. The capital required to replace your spending can be 25% to 35% lower than the capital required to replace your paycheck. Run that number first. Then decide how much risk you are willing to take to get there.

The Conservative Tier: 3% to 4% Yield

At a 3.5% yield, generating $144,000 takes roughly $4.1 million in invested capital. At 4%, the figure drops to $3.6 million. This is the range for dividend-growth blue chips and broad equity income funds.

Johnson & Johnson (NYSE:JNJ) yields 2.3%, a touch below the tier but with 64 consecutive years of dividend increases. The board lifted the quarterly payout to $1.34 in May 2026, up from $0.285 back in 2005. Procter & Gamble (NYSE:PG) yields 3.0% and just delivered its 70th consecutive annual dividend increase. Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) charges 6 basis points and holds names like Merck, Chevron, Lockheed Martin, and Coca-Cola, giving you sector breadth in one ticket.

The tradeoff is obvious. You need the most capital. The payoff is principal that tends to appreciate and an income stream that historically outpaces inflation.

Story Continues

The Moderate Tier: 5% to 7% Yield

At 6%, the required capital falls to $2.4 million. This range is where REITs, preferred shares, covered-call ETFs, and high-dividend equity funds live.

Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.

Realty Income (NYSE:O) pays monthly and yields 5.4%, putting the capital requirement near $2.7 million. The triple-net REIT has logged 114 consecutive quarterly dividend increases and 670 consecutive monthly payments, with portfolio occupancy at 99% and 2026 AFFO guidance of $4.41 to $4.44 per share. Outside REITs, covered-call income ETFs and preferred-stock funds round out the tier.

Dividend growth slows in this band. Realty Income raised the monthly payment from $0.27 to $0.2705 earlier this year, a meaningful but measured bump. Covered-call funds cap your upside in rallies. You trade a slice of long-term appreciation for current cash.

The Aggressive Tier: 8% to 12% Yield

At 10%, the math becomes seductive: $1.4 million generates $144,000. Ares Capital (NASDAQ:ARCC), the largest publicly traded business development company, yields 10.2% with a $0.48 quarterly distribution that has held steady for 8 consecutive quarters. The portfolio earns a weighted average yield of 10.3% and is 72% floating rate. Mortgage REITs, leveraged covered-call funds, and high-yield bond funds occupy similar ground.

Read the price chart with eyes open. ARCC shares are down about 6% over the past year and trade below book value at almost $20. The income is high; the principal moves.

The Compounding Trap Most Income Investors Miss

Johnson & Johnson's quarterly dividend grew from $0.285 in 2005 to $1.34 in 2026, roughly a fivefold increase. Ares Capital's quarterly payout rose from $0.40 in 2020 to $0.48 today and has been flat for the past two years. That difference highlights the tradeoff between yield and growth.

A portfolio generating $144,000 annually from dividend-growth stocks may produce substantially more income a decade from now. A high-yield portfolio starts with a larger check, but that check may barely grow at all. Meanwhile, inflation keeps reducing its purchasing power. The danger is focusing so heavily on today's yield that you overlook what your income stream might look like ten or fifteen years down the road.

Three Moves That Matter

Audit your actual spending against your salary. The national savings rate has fallen to 3.7%, which means most paychecks are fully consumed, but pre-retirement expenses like commuting and retirement contributions still disappear at the finish line. Blend the tiers. A portfolio that is 60% conservative, 25% moderate, and 15% aggressive can land near a 5% blended yield with meaningful growth, cutting capital required to roughly $2.9 million without parking everything in BDCs. Place high-yield holdings inside an IRA or Roth. Ordinary-income distributions from BDCs and mortgage REITs are taxed at your marginal rate; qualified dividends from JNJ or PG are not. Asset location can be worth a full percentage point of after-tax yield.

If You’ve Been Thinking About Retirement, Pay Attention (sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:

Answer a Few Simple Questions. Get Matched with Vetted Advisors Choose Your  Fit

Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer commented on, saying that tech stocks cannot be trusted to lead anymore. Cramer mentioned the company while highlighting his current sentiment around drug stocks, as he remarked:

Obviously, the other leadership groups are a little more palatable to me… Healthcare, eureka, I found it. This is the leadership group that we’ve been looking for. Take Johnson & Johnson. It’s been shedding slower-growing divisions like Kenvue, its consumer products business, as well as its commodity orthopedic operations, focusing on fast-growing drugs. I like that. It’s got a ton of them. It’s got an AAA balance sheet, better than the US government. I like the drug stocks here. I like the UnitedHealths here.

Photo by Artem Podrez on Pexels

Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases. Cramer mentioned the company’s “great new drug profits” during the June 5 episode, as he said:

Now, you can make good money for a while if you go all in on what’s hot, but I never do it because I know it’ll eventually blow up in your face… That’s why we run a diversified fund for the Investing Club. When you’re diversified, at any given moment, you’re going to own some losers, though, or at least some stocks that aren’t working. These stocks will lag while the data center roars, but they preserve your sanity when you get a tsunami-like sell-off in the hottest stocks out there.

Well, the tsunami of data center selling is here, and today’s the day when I’m kind of patting myself on the back for keeping the Charitable Trust diversified, not going all in on the data center complex. Today’s the day when we’re grateful for our Johnson & Johnson position. Great new drug profits. Triple-A balance sheet, better than the United States… See, the lesson’s clear, people. The P&Gs and the J&Js in your portfolio allow you to safely own the techs. They’re kind of like permits. But if you don’t take something off the table of the techs when you’re up big, I think you’re going to live to regret it.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Story Continues

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Guinness Global Innovators, an investment management company, recently released its Q1 2026 quarterly investor update for its “Guinness Global Equity Income Fund”. A copy of the letter is available to download here. The Fund focuses on providing investors with global exposure to dividend-paying companies. In Q1 2026, the fund returned was -0.5% (GBP), compared to -1.6% for the MSCI World Index and 0.1% for the IA Global Equity Income sector average. The quarter saw notable changes in market sentiment driven by geopolitical tensions and energy market disruptions. The market shifted focus from growth sectors, particularly mega-cap technology and software, to value-oriented, defensive, international, and ‘physical economy’ stocks. The Fund gained from this transition towards defensive and value areas in the quarter. The letter discusses the impact of macro events and market dynamics on Q1 performance and examines software industry valuations amid rising concerns around AI-driven disruption. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.

In its first-quarter 2026 investor letter, Guinness Global Equity Income Fund highlighted stocks like Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) is a leading global healthcare company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. On June 11, 2026, Johnson & Johnson (NYSE:JNJ) closed at $238.33 per share. One-month return of Johnson & Johnson (NYSE:JNJ) was 5.13%, and its shares gained 51.71% over the past 52 weeks. Johnson & Johnson (NYSE:JNJ) has a market capitalization of $573.71 billion.

Guinness Global Equity Income Fund stated the following regarding Johnson & Johnson (NYSE:JNJ) in its Q1 2026 investor letter:

"Johnson & Johnson (NYSE:JNJ) was the Fund’s top-performing stock in Q1 2026, rising 18.7% as markets gained confidence that the company has been effectively replacing revenues of Stelara, a drug that accounted for more than 10% of sales at its peak, but ‘loss of exclusivity’ led to numerous biosimilar launches in 2025. That confidence was fuelled by a very solid earnings print with which the firm reported full-year sales growth of 6%, despite a 7.5 percentage point headwind from Stelara’s loss of exclusivity. Organic sales growth accelerated significantly, rising from 3.7% in Q3 (and 2.4% in Q2) to 7.9% in Q4. Performance was broad-based, with strong momentum across a number of key drugs within the firm’s pharma division, with Tremfya (Crohn’s disease) and Darzalex (Myeloma) the stand-outs. Alone, these drugs were able to provide $4.2bn in sales growth, nearly fully offsetting the $4.3bn decline from Stelara. The remaining drugs in the pharma portfolio were able to grow another $3.6bn, a 6% contribution to the overall growth of the pharma division. MedTech was similarly encouraging, with sales ahead of consensus by 40 basis points and strength across Orthopaedics (recently spun out), Surgery, and Vision, supported by the firm’s recent Shockwave acquisition. Importantly, management reiterated solid 2026 guidance at 5.9% (at the mid-point), and reiterated confidence in achieving the upper end of its 5-7% long-term sales growth target, with a credible path to double-digit growth later in the decade, benefitting from the roll-off of patent cliff headwinds..." (Click here to read the full text)

Story Continues

CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says

Johnson & Johnson (NYSE:JNJ) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 113 hedge fund portfolios held Johnson & Johnson (NYSE:JNJ) at the end of the first quarter, up from 104 in the previous quarter. While we acknowledge the potential of Johnson & Johnson (NYSE:JNJ) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Johnson & Johnson (NYSE:JNJ) and shared a bullish thesis on the company. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Key Points

The company is expanding both approved and pipeline therapies. New indications could expand the market for existing drugs. Long-term cash flow growth could support future dividend increases.10 stocks we like better than AbbVie ›

AbbVie (NYSE: ABBV) boasts a pretty attractive dividend at more than 3%.

That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and Amgen (NASDAQ: AMGN), all of which yield dividends of roughly 2% or less.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

But dividends don't increase just because management wants them to. They rise because the business generates enough cash to support them.

Following the money

This week, AbbVie presented new data from its blood cancer portfolio at the European Hematology Association (EHA) Congress.

This is one of the world's largest medical conferences focused on blood cancers and disorders, bringing together thousands of physicians, researchers, pharmaceutical companies, and healthcare professionals to present new clinical trial data and discuss emerging treatments.

The reason EHA is important is that companies often use the conference to release new data on cancer drugs, particularly therapies targeting blood cancers. Positive results presented at EHA can support regulatory approvals, label expansions, partnerships, and future revenue growth. That's why AbbVie showcased its new clinical results there.

The company's most recent presentations included data on approved therapies as well as several pipeline candidates. In total, AbbVie showcased 21 presentations spanning multiple blood cancers, including chronic lymphocytic leukemia, follicular lymphoma, multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma.

AbbVie generated about $61 billion in revenue during 2025, and while immunology drugs receive most of the attention, oncology remains an important contributor.

The company's oncology portfolio generated about $6.7 billion in revenue in 2025. That's not insignificant.

That revenue helps fund research and development, debt reduction, share repurchases, and dividends.

Indeed, oncology helps diversify AbbVie's business.

Diversifying the pipeline

You may remember the company's dependence on Humira.

At its peak, Humira was one of the best-selling drugs in pharmaceutical history, generating about $21 billion in annual revenue.

That concentration created a significant risk because patents eventually expire. And when Humira lost U.S. exclusivity in 2023, and biosimilar generics entered the market, Humira revenue began declining rapidly.

Management saw this challenge coming years in advance and responded by aggressively building new growth platforms across immunology, oncology, and neuroscience.

Image source: Getty Images.

Today, drugs such as Skyrizi and Rinvoq (used to treat Crohn's disease, ulcerative colitis, and arthritis) are helping offset Humira's decline, while the company's oncology portfolio provides another important source of revenue and cash flow. The result is a much more diversified business than just a few years ago.

Today, AbbVie generates revenue across immunology, neuroscience, and oncology. That has reduced dependence on any single product and created a more resilient cash flow profile.

And that's why the EHA presentations are relevant.

AbbVie is actively expanding the use of existing drugs while advancing newer therapies that could eventually offset declines from older products. The company highlighted encouraging efficacy data across multiple studies, including late-stage programs and investigational treatments targeting difficult-to-treat blood cancers.

Of course, you can't guarantee successful drug development.

Clinical setbacks happen, and not every program succeeds. It's just part of the overall process of developing new therapies.

Still, AbbVie's oncology portfolio is no longer dependent on a single drug. The company now has multiple approved products, several late-stage opportunities, and a broader pipeline than it did just a few years ago.

Now consider that the latest clinical updates will strengthen the revenue engine supporting the dividend over the long term.

AbbVie's oncology business already generates billions of dollars annually, and management continues working to ensure that oncology remains a growth driver rather than a mature business.

That's why the company continues investing heavily in expanding existing therapies into new indications while advancing next-generation treatments for blood cancers and solid tumors.

Every successful clinical trial creates the potential for new approvals, larger patient populations, and longer revenue runways. And because cancer treatments often command premium pricing and can remain on the market for many years, successful oncology drugs can become meaningful cash-generating assets.

And ultimately, it's cash flow that pays dividends.

Should you buy stock in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!

Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of June 12, 2026.

Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Key Points

Parabilis and another recent IPO stock each raised more than Moderna -- which had previously been the biggest biotech IPO. Parabilis’ technology could be a game changer and potentially used across treatment areas.These 10 stocks could mint the next wave of millionaires ›

This year is turning out to be a massive one for initial public offerings, with Cerebras Systems delivering the biggest so far and SpaceX on track to launch the largest ever. On top of that, Anthropic and OpenAI recently filed confidentially with regulators, suggesting they may make market debuts soon.

That activity has been in the technology sector, but another area that's looking hot is the industry of biotech. Kailera Therapeutics got the ball rolling in April, with a biotech IPO that topped the biggest one to date -- that of Moderna, which raised a record $604 million in 2018. And just this week, Parabilis Medicines (NASDAQ: PBLS) topped them all, raising $670 million. And on the stock's first day of trading, it soared 58% to close at a little over $31.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Investors are clearly excited about this biotech company exploring an innovative way to fight cancer and potentially other diseases. Now the question is: After this explosive IPO, is it too late to buy the stock?

Image source: Getty Images.

Taking on "undruggable" targets

First, let's start out by taking a closer look at Parabilis. The company launched in 2015, built on many years of research out of Greg Verdine's Harvard University lab. He was a co-founder and chief executive officer in the company's earliest days. Verdine's team found a way to target what previously was thought to be "undruggable" -- these are certain proteins that are inside cells and lack the concave surfaces that allow drugs to bind and take action.

Verdine's team created a new drug type, forming peptides into an alpha-helix so that they could enter cells, bind to flat surfaces, and work to fight disease. And so was born the company's Helicon platform.

Today, Mathai Mammen, former global head of research and development at Johnson & Johnson, is CEO of Parabilis -- at the pharma giant, he led his team to the approvals of nine medicines across oncology, immunology, and neuroscience. So Mammen has what it takes to lead Parabilis through the current and next stages of clinical development and into commercialization.

"Promising" results in patients

The biotech's lead candidate, zolucatetide, is set to begin a phase 3 study in desmoid tumors, noncancerous growths that have limited treatment options, in the first half of next year. Parabilis has studied zolucatetide in more than 150 patients so far and delivered "promising" data in a range of tumor types, the company wrote in its prospectus.

Zolucatetide is involved in four phase 1 studies, including hepatocellular carcinoma and colorectal cancer. And the biotech is also developing candidates in preclinical studies and aims to expand this technology into other therapeutic areas beyond oncology in the future.

Parabilis says that Helicons are the only modality out there right now that allows for the entering of cells and the binding to flat surfaces. This ability to make "undruggable" targets "druggable" could be big, particularly if it may be extended across many treatment areas. About 80% of validated disease targets are undruggable today, according to Parabilis.

Parabilis' deepening loss

Now, let's consider the recent IPO and the company's financial picture. Proceeds from the offering will go toward funding zolucatetide's phase 3 study, as well as earlier studies in other indications and earlier-stage research. The company's loss has progressively deepened, to $145 million last year, as R&D costs advanced to $125 million. This isn't surprising for a biotech company at this stage. But these losses and need for ongoing spending to support its programs make Parabilis -- and other biotechs at this moment in their growth stories -- risky investments.

So, considering all of this and the recent double-digit gain on IPO day, is it too late to get in on Parabilis? This biotech offers interesting -- and potentially game-changing -- technology, but it may take several years for this, if successful, to translate into revenue. So, regardless of the stock price, Parabilis isn't the best choice for cautious investors.

If you're an aggressive investor, however, and you're looking for a biotech that potentially may be a big winner down the road -- and you have the patience to buy and hold for several years, Parabilis may be right for you. That said, there's no need to rush in immediately after this spectacular IPO gain. Instead, you're better off waiting for an opportunity to buy on the dip.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 926%* — a market-crushing outperformance compared to 203% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you joinStock Advisor.

See the stocks »

*Stock Advisor returns as of June 12, 2026.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Moderna. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Johnson & Johnson (JNJ) wird als hochwertige Dividendenaktie beschrieben, die defensive Gesundheitsexposition mit ausgezeichneter finanzieller Stärke und einer langen Geschichte an Shareholder-Renditen kombiniert. Die Firma operiert durch Innovative Medicine und MedTech nach der Trennung ihrer Consumer-Health-Division, fokussierend sich auf patentierte Arzneimittel und hochmarginale medizinische Geräte, die von starken Wechselkosten und regulatorischen Barrieren profitieren. In 2024 erzielte JNJ 88,8 Milliarden US-Dollar an Umsatz mit einer operativen Wachstumsrate von 5,9 %, unterstützt durch eine intensive Reinvestition von fast 17 Milliarden US-Dollar oder 19,4 % der Verkäufe in Forschung und Entwicklung, um seine zukünftige Pipeline zu sichern. Trotz dieser Investitionsintensität hält die Firma ein robustes Profitabilitätsprofil und erzeugte 20 Milliarden US-Dollar an freiem Cash-Flow, unterstützt durch Reinvestitionen und Shareholder-Verteilungen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Johnson & Johnson (JNJ) hat in den letzten Monaten eine starke Performance gezeigt, mit einem Kursanstieg von etwa 7,7% innerhalb der letzten 30 Tage und etwa 15% im Laufe des Jahres. Die Frage ist nun, ob es noch Potenzial für einen weiteren Anstieg gibt oder ob die Zukunft bereits in den Preisen eingepreist ist. Derzeit wird Johnson & Johnson auf einem Kurs von $238,49 gehandelt, was einer Bewertung entspricht, die etwa 36,2% unter dem intrinsic Value liegt und nur 6,0% über den Analystenzielen. Die Frage ist nun, ob es noch einen realen Upside gibt oder ob die Zukunft bereits in den Preisen eingepreist ist.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Mergers and acquisitions (M&A) activity across pharmaceutical and biotech sectors has accelerated significantly in 2026, extending the strong recovery that began in 2025.

A recent surge in dealmaking underscores the industry's focus on portfolio expansion and continuous pipeline innovation, alongside a growing emphasis on AI-driven drug discovery. Oncology and immuno-oncology companies have always been at the top of acquisition targets. Major players are actively pursuing licensing agreements and collaborations around promising drugs and candidates to further strengthen and diversify their core portfolios.

Quick Take on Recent M&A Deals

Pharma conglomerate Johnson & Johnson recently announced that it will acquire Firefly Bio for $1 billion and gain access to its Firelink degrader antibody conjugate platform. The deal strengthens Johnson & Johnson's oncology pipeline by adding a targeted approach for KRAS-driven cancers, supporting its efforts to develop treatments for some of the most common and challenging solid tumors.

Other pharma giants Eli Lilly LLY and Novartis NVS have been on an acquisition spree this year.

Lilly recently announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company, expanding its infectious disease research and development capabilities.

Lilly has been actively expanding its pipeline through acquisitions. LLY is all set to acquire Ajax Therapeutics, which will add AJ1-11095, a potential first-in-class oral type II JAK2 inhibitor currently in phase I testing for myelofibrosis patients previously treated with type I JAK2 inhibitors, to its pipeline.  The company also announced a deal to acquire clinical-stage biotechnology company Kelonia Therapeutics, Inc, a pioneer in vivo gene delivery.

The company had earlier agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, which will add orexin-based sleep disorder candidate cleminorexton to its pipeline. Lilly also struck a deal worth up to $2.4 billion for Orna Therapeutics, to gain access to its circular RNA-based immune cell engineering platform. Lilly also acquired Ventyx Biosciences to strengthen its portfolio of oral therapies targeting inflammatory diseases.

Swiss pharma bigwig Novartis, too, has been very active on the M&A front.  NVS is set to acquire Excellergy Inc., strengthening its immunology pipeline with a focus on food allergies and other IgE-mediated conditions. The deal brings in EXL-111, a phase I, half-life-extended anti-IgE antibody.

Earlier this year, Novartis acquired Avidity Biosciences, adding its antibody oligonucleotide conjugate (AOC) platform and three late-stage programs, further bolstering its neuromuscular pipeline.

Story Continues

Last month, Merck MRK acquired Terns Pharmaceuticals for $53 per share in cash. The deal adds TERN-701, a potential best-in-class treatment for chronic myeloid leukemia that recently received FDA Breakthrough Therapy Designation. The acquisition strengthens Merck's oncology pipeline.

Among biotech giants, Gilead Sciences, Inc. GILD is ramping up its external innovation strategy through targeted acquisitions to strengthen its pipeline and reduce reliance on its core HIV franchise.

Gilead and partner Lakefront Biotherapeutics (formerly known as Galapagos) recently acquired Ouro Medicines, adding gamgertamig, a clinical-stage BCMAxCD3 T-cell engager, to strengthen their autoimmune disease and inflammation pipeline.

Last month, Gilead acquired Tubulis, a clinical-stage biotech focused on developing next-generation antibody-drug conjugates (ADCs), strengthening its oncology pipeline.

Earlier this year, GILD acquired Arcellx for about $7.8 billion. The acquisition gives Gilead full ownership of anito-cel, an investigational late-stage CAR-T therapy for multiple myeloma with a potential U.S. decision by December 2026.

Another biotech giant Biogen recently acquired Apellis Pharmaceuticals $41 per share in cash plus contingent value rights worth up to an additional $4 per share tied to future sales milestones. The acquisition adds two commercialized therapies, Empaveli and Syfovre, to Biogen's portfolio. Together, the drugs generated $689 million in sales in 2025. The transaction strengthens Biogen's presence in immunology and rare diseases while establishing a foothold in nephrology.

Earlier this week, GSK plc GSK announced that it will acquire clinical-stage biopharmaceutical company Nuvalent for $10.6 billion, gaining three lung cancer assets, including late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib, both under FDA review. The deal strengthens GSK's oncology pipeline, expands its presence in lung cancer, and is expected to contribute to sales and operating profit growth beginning in 2027.

GSK earlier acquired RAPT Therapeutics to strengthen its immunology pipeline. The company also bought 35Pharma, adding HS235, a potential best-in-class therapy for pulmonary hypertension.

Last week, Servier (an independent international pharmaceutical group governed by a foundation) agreed to acquire the muscular dystrophy business of Edgewise Therapeutics in a deal worth up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in milestone payments.

Road Ahead in 2026

Consolidation remains a key theme as companies seek to offset patent cliffs and diversify revenue streams. Acquisitions offer a faster, less risky route than in-house development, especially as innovation cycles shorten.

With strong cash reserves and increasing adoption of advanced technologies like AI, M&A activity is expected to remain robust through 2026. Smaller biotechs, often constrained by funding, will likely remain prime acquisition targets, further fueling deal momentum.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report

Novartis AG (NVS) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Quick Read

JNJ leads the 45% dividend-growth sleeve in the giving bucket, where decades of healthcare dividend raises anchor an honest planning range of 4 to 6 percent. O's 5.3% monthly yield and DUK's EPS growth target of 5 to 7% fill the REIT and utility sleeves that stabilize the giving portfolio's income stream. Roughly $250,000 of dedicated dividend capital, kept separate from base retirement assets, funds $15,000 a year in grandparenting at a realistic 6% blended yield. Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.

A Utah couple with two children and four grandchildren nearby has a retirement goal that has nothing to do with yachts or sports cars. They want to be the grandparents who can say "yes." Yes to helping with travel hockey. Yes to a week at the lake. Yes to Disney. Yes to contributing toward a first car, a senior trip, or a college expense. The question is not whether they can afford retirement. It is whether they can afford the kind of grandparents they want to be.Gorodenkoff / Shutterstock.com

That distinction matters. Most retirement plans focus on housing, healthcare, food, and travel. Few include a dedicated line item for family generosity. But once a couple decides they want to provide meaningful financial help to children and grandchildren, that spending needs to be treated like any other retirement expense. The challenge is creating enough income to support those gifts year after year without steadily eroding the portfolio that must support the rest of retirement.

Three Tiers Of Saying Yes

Start with the family-giving budget alone, layered on top of normal retirement expenses. The goal here is not to fund retirement itself. It is to create a dedicated pool of income for helping children and grandchildren without constantly dipping into principal.

The Helpful Grandparents tier funds about $5,000 a year of youth sports, music lessons, birthday gifts, school trips, and the occasional extra that makes a grandchild's life easier. At a 4% portfolio yield, that requires roughly $125,000 of dedicated capital. At 6%, about $83,000. At 8%, about $62,500.

The Generous Grandparents tier funds about $15,000 a year. This is where the grandparents start saying yes more often: sports and camps, meaningful 529 contributions, help with special opportunities, and a substantial contribution toward a family vacation every few years. The capital required is roughly $375,000 at a 4% yield, $250,000 at 6%, and $187,500 at 8%.

Story Continues

The Family Legacy Builders tier funds about $30,000 a year. At this level, the grandparents can help with first cars, make significant college contributions, cover much of a family vacation, and absorb the occasional emergency without disrupting their own retirement plan. That requires roughly $750,000 at a 4% yield, $500,000 at 6%, or $375,000 at 8%, again as a separate bucket on top of the assets needed to fund their own retirement.

Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.

Taxes matter. Depending on the mix of qualified dividends, interest income, REIT distributions, and other income sources, retirees may keep only 80 to 85 cents of each yield dollar after federal and state taxes. A couple hoping to spend $15,000 a year on children and grandchildren may therefore need an income stream closer to $17,000 to $19,000 annually to reach that goal consistently.

Building The Income Engine

An 8% yield assumption is aggressive and often requires reaching into preferred shares, mortgage REITs, covered-call funds, or other income vehicles that can sacrifice principal stability when markets turn against them. For grandparents whose goal is dependable support over twenty years or more, a 4% to 6% portfolio yield is the more realistic planning range. The objective is not maximizing income this year. It is making sure the "yes" fund is still there a decade from now.

A workable giving portfolio might consist of roughly 45% dividend-growth blue chips in sectors such as healthcare and consumer staples, where payouts have increased steadily for decades, 20% in income-producing real estate, 15% in utilities and other defensive income investments, 15% in a Treasury ladder that locks in current yields, and 5% in cash. The cash allocation is more important than it looks. Holding one to two years of planned gifts and family assistance in cash helps ensure that a market downturn never forces the grandparents to tell a grandchild no simply because stocks happen to be down that year.

The Compounding Power Of Memories

Consider a couple with $250,000 dedicated to family giving. They can leave that money untouched and eventually pass it on as part of an inheritance, or they can use it to generate roughly $15,000 a year for two decades of grandparenting. The inheritance may arrive when the grandchildren are in their 30s or 40s, established in their careers and raising families of their own. The annual giving arrives when it can shape decisions: helping a grandchild stay in music lessons, attend summer camp, join a travel team, visit Disney with the family, or choose a college that would otherwise be out of reach. Even more importantly, participating financially in grandchildren's activities often translates into time and communication with those grandchildren about those activities. Sharing life experiences can feel far more meaningful than simply sharing dollars.

Money has timing value as well as dollar value. A contribution made when a child is 12 or 17 often has a larger impact than the same dollars arriving decades later. The purpose of the dividend-growth portion of the portfolio is to help that giving power keep pace with inflation so the grandparents can keep saying yes as the years go by.

The Real Risk Is Dying With Unused Assets

Many retirees spend years worrying about running out of money. Far fewer worry about the opposite outcome: reaching their late 80s with a larger portfolio than they started retirement with and a long list of opportunities they never funded. The purpose of a family-giving budget is not to preserve capital. It is to convert a portion of that capital into experiences, opportunities, and memories while everyone is young enough to enjoy them.

For a couple targeting the Generous Grandparents lifestyle, the number to remember is roughly $250,000 of dedicated capital. At a realistic 6% blended yield, that portfolio can support about $15,000 a year of family generosity, separate from the assets needed to fund their own retirement. The goal is not simply to leave money behind. It is to put some of it to work while the grandchildren still call every week.

If You’ve Been Thinking About Retirement, Pay Attention (sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:

Answer a Few Simple Questions. Get Matched with Vetted Advisors Choose Your  Fit

Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Quick Read

JNJ's AAA-rated balance sheet and 64 consecutive years of dividend growth anchor a business generating $19.7 billion in annual free cash flow. STELARA sales collapsed 60% from biosimilar pressure, but TREMFYA surged 68% and J&J's Innovative Medicine segment still grew double digits. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.

I keep buying Johnson & Johnson (NYSE:JNJ) because the market keeps handing me a discount on a company that refuses to act like the slow, sleepy legacy name Wall Street wants to price it as. The Fed will say what it says this month. The headlines will do what headlines do. I am still hitting the buy button, and here is the honest reason why.Mario Tama / Getty Images News via Getty Images

The thesis is simple. After spinning off Kenvue, J&J became a leaner, higher-margin business built around two engines: innovative medicine and medical technology. It funds operations and rewards shareholders from internal cash flow, independent of central bank policy. When Fed-driven panic puts a compounding machine on sale, I show up with a shopping cart.

The first piece of evidence is the cash return. The board raised the quarterly payout 3.1% to $1.34 per share, extending 64 consecutive years of dividend growth. The yield sits at 2.24% and is backed by $19.7 billion in 2025 free cash flow and one of only two AAA-rated balance sheets in corporate America. That combination is rare, and it is exactly what I want anchoring the income side of a long-horizon portfolio.

The second piece of evidence is operating performance that does not match the "stagnant legacy pharma" caricature. Q1 2026 revenue came in at $24.06 billion, up 9.9% year over year, with adjusted EPS of $2.70, the fourth consecutive consensus beat. Innovative Medicine grew 11.2%, MedTech 7.7%. DARZALEX did $3.96 billion (+22.5%), TREMFYA $1.61 billion (+68.3%), and CARVYKTI $597 million (+62.1%). Management then raised full-year guidance to $100.30 billion to $101.30 billion in revenue and $11.45 to $11.65 in adjusted EPS, telling investors they are "solidifying its path to double-digit growth by the end of the decade."

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.

The third piece is valuation. At $238.49, JNJ trades at a forward earnings multiple of roughly 20 on a business compounding earnings, raising guidance four quarters in a row, and protecting a fortress balance sheet. Yes, the stock is up 16.52% year to date versus the S&P 500 at 6.38%, and I still find it cheap relative to the pipeline behind it.

Story Continues

Now the honest risk. STELARA is being eaten alive by biosimilars. Q1 sales dropped to $656 million, a 59.7% decline, a roughly 920 basis point drag on Innovative Medicine. Layer in ongoing talc litigation, including a $330 million charge in Q1 2026, and the bear case writes itself. Here is why it has not moved me: TREMFYA alone is capturing the share STELARA loses, and the segment still grew double digits through the erosion. The litigation is real, but so is $19.7 billion of annual free cash flow that can absorb settlements without touching the dividend.

So what keeps the buy button active? An aging global population, a pipeline stacked with oncology and immunology catalysts, the planned Orthopaedics separation, and a CEO telling me "the depth and strength of our portfolio and pipeline is unrivaled." The Fed can shake Wall Street all month. I will keep buying the Dividend King that does not need the Fed to win.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.

View Comments